Stocks to buy in 2026 for long term: Suzlon, Fortis Healthcare among 5 stocks that could give 10-60% returns
Fortis Healthcare has been recommended by analysts as a long-term investment opportunity for 2026, featuring in a list of stocks projected to deliver significant returns, potentially between 10-60%.
May 27 2026 07:26:44
Fortis Healthcare Ltd - 532843 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Fortis Healthcare has published the audio recording of its investor/analyst meet held on May 25, 2026. The meet discussed the company's Q4 FY26 and full financial year results, providing investors access to management commentary.
May 25 2026 20:53:26
Six pharma stocks that should be on your radar today over various news triggers
Fortis Healthcare is featured in a CNBC-TV18 article listing pharma stocks to watch, with the commentary focusing on various factors influencing share prices across the sector rather than specific company-driven events.
May 25 2026 07:43:02
Fortis Healthcare Limited
Fortis Healthcare's board has recommended a final dividend of Rs.0.10 per equity share for the financial year 2025-26. The record date for this dividend will be announced later.
May 22 2026 22:09:40
Fortis Healthcare Ltd - 532843 - CSR Policy
Fortis Healthcare board approved consolidated financial results for FY26, reporting Rs.9,128 crore revenue and Rs.1,064 crore net profit. The board also declared a final dividend of Rs.1 per equity share.
May 22 2026 21:02:58
Fortis Healthcare Ltd - 532843 - Cost Auditor Appointment
Fortis Healthcare's Board of Directors approved the audited financial results for FY26 and recommended a final dividend of Rs.1 per equity share. The board also appointed a cost auditor and approved the Corporate Social Responsibility Policy, while noting ongoing regulatory investigations.
May 22 2026 20:55:23
Fortis Healthcare Q4 profit up 45% on lower exceptional losses, higher revenue
Fortis Healthcare reported a 12.4% year-on-year increase in consolidated revenue to ₹2,007 crore for Q4 FY25. Operating EBITDA rose by 14.3% to ₹435 crore, with margins improving to 21.7%. However, net profit declined by 7.4% to ₹188 crore, primarily due to a one-off impairment charge. The board also recommended a final dividend of ₹1 per equity share for FY25.
May 22 2026 20:53:28
Fortis Healthcare Ltd - 532843 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Fortis Healthcare announced strong Q4 FY26 and full-year FY26 results. Q4 FY26 consolidated revenue grew 17.8% YoY to Rs.2,365 crore, while PAT surged 44.2% to Rs.271 crore. For FY26, revenue increased 17.3% to Rs.9,128 crore and PAT rose 31.5% to Rs.1,064 crore. The board also recommended a dividend of Rs.1 per share.
May 22 2026 20:34:13
Fortis Healthcare Ltd - 532843 - Corporate Action-Board approves Dividend
Fortis Healthcare's board recommended a final dividend of ₹1.00 per equity share for FY2025-26. This translates to 10% of the face value and a total cash outflow of approximately ₹7,549.58 lacs, subject to shareholder approval.
May 22 2026 20:29:09
Fortis Healthcare Ltd - 532843 - Board Meeting Outcome for Approval Of Financial Results For The Quarter And Year Ended March 31, 2026 And Recommendation Of Final Dividend For The Year Ended March 31, 2026
Fortis Healthcare announced strong FY26 financial results, with cons. net profit up 31.48% to ₹1,064.19 cr and revenue up 17.28% to ₹9,127.84 cr. A final dividend of ₹1.00 per share was recommended by the board.
May 22 2026 19:55:19
Read More